Literature DB >> 10146868

Episode-free days as end-points in economic evaluations of asthma therapy.

A S Zbrozek.   

Abstract

Mesh：

Year:  1994        PMID： 10146868     DOI： 10.2165/00019053-199405010-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  1 in total

1.  The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

Authors:  M J Sculpher; M J Buxton
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981
  1 in total
  3 in total

1.  Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

Authors:  T Volmer; A Kielhorn; H H Weber; K J Wiessmann
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 2.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  Cost effectiveness of fluticasone and budesonide in patients with moderate asthma.

Authors:  K O Steinmetz; T Volmer; M Trautmann; A Kielhorn
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.